Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Large Is the Androgen Deprivation Therapy Market Expected to Be in 2029?

In the past few years, the market size of androgen deprivation therapy has seen substantial growth. There is an expected increase from $7.81 billion in 2024 to $8.31 billion in 2025, with a compound annual growth rate (CAGR) of 6.3%. The growth observed in the historic period has been led by factors such as a global rise in prostate cancer cases, an expanding aging male demographic, a high recurrence rate of prostate cancer, enhanced survival rates prompting extended treatment, and growing cognizance regarding early prostate cancer screening.

Strong expansion is predicted for the androgen deprivation therapy market in the coming years, with an expected growth to $10.49 billion in 2029 and a compound annual growth rate (CAGR) of 6.0%. This projected growth over the forecast period is due to factors such as the rising acceptance of combination therapies in oncology, an increase in hormone-sensitive cancers, a high number of localized and advanced prostate cancer diagnoses, expanded usage of ADT for non-oncologic hormonal conditions, and a growing preference among patients for non-invasive treatments. Key trends anticipated for the forecast period involve advancements in depot formulations and delivery methods, the creation of oral ADT drugs, the rise of long-acting ADT injectables, the introduction of innovative androgen receptor inhibitors, and technological advancements in digital pathology and diagnostics.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25692&type=smp

What Are The Contributors To Demand In The Androgen Deprivation Therapy Market?

The escalation in prostate cancer cases is anticipated to propel the expansion of the androgen deprivation therapy market in the imminent years. Prostate cancer, which starts in the prostate gland responsible for creating seminal fluid in the male reproductive system, is seeing a rising trend primarily due to extended lifespans, as advancing age notably increases the likelihood of this disease. The primary treatment approach for prostate cancer is Androgen deprivation therapy (ADT), which works by reducing androgen levels that stimulate tumor growth. This treatment is commonly used in advanced or metastatic phases to decelerate disease progression. For example, a report published by Prostate Cancer UK, a prostate cancer research, awareness, and support organisation based in the UK, showed that the number of prostate cancer diagnoses in England rose from 50,751 cases in 2022 to 55,033 cases in 2023, clearly showing annual growth. As a result, the growing incidence of prostate cancer is driving the surge in the androgen deprivation therapy market.

What Segmentation Categories Are Included In The Androgen Deprivation Therapy Market Analysis?

The androgen deprivation therapy market covered in this report is segmented –

1) By Type: Medicine, Surgery, Other Types

2) By Route Of Administration: Injectable, Oral

3) By Patient Demographics: Men Aged 40-60, Men Aged 61-75, Men Above 75

4) By Application: Prostate Cancer, Other Applications

5) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Medicine: LHRH Agonists, LHRH Antagonists, Anti-Androgens, CYP17 Inhibitors, Steroidal Anti-Androgens, Non-Steroidal Anti-Androgens, Estrogen-Based Therapies, Combination Therapies

2) By Surgery: Bilateral Orchiectomy, Subcapsular Orchiectomy, Simple Orchiectomy

3) By Other Types: Radiopharmaceutical Therapy, Gene Therapy, Immunotherapy, Targeted Therapy, Cryotherapy, High-Intensity Focused Ultrasound (HIFU

What Upcoming Trends Are Expected To Impact The Androgen Deprivation Therapy Market Globally?

Leading corporations in the androgen deprivation therapy market are concentrating on the creation of cutting-edge solutions such as combination therapies to enhance the results of advanced prostate cancer treatments. This involves employing multiple treatment types, including hormone therapy and chemotherapy, to bolster therapeutic efficiency and slow the development of the disease. For example, in August 2022, Bayer AG, a German company specializing in life sciences, obtained approval from the U.S. Food and Drug Administration for the additional use of darolutamide in conjunction with docetaxel to treat metastatic hormone-sensitive prostate cancer (mHSPC). The newly authorized combination therapy seeks to improve survival rates and postpone disease escalation in patients with metastatic hormone-sensitive prostate cancer (mHSPC), a scenario where the cancer is spread but remains responsive to hormone therapy. The therapy’s key distinguishing feature is darolutamide – an orally ingested medication that concentrates on androgen receptors. Its distinct molecular structure allows it to securely bind to these receptors, functionally limiting their activity to assist in preventing the growth and dispersion of prostate cancer cells.

Who Are The Top-Ranked Companies In The Androgen Deprivation Therapy Market Today?

Major companies operating in the androgen deprivation therapy market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Astellas Pharma Inc., Ipsen S.A., Dr. Reddy’s Laboratories Ltd., Orion Corporation, Arvinas Inc., Ferring Pharmaceuticals SA, Tolmar Pharmaceuticals Inc., Besins Healthcare S.A., Veru Inc., Kintor Pharmaceutical Limited, Foresee Pharmaceuticals Co. Ltd., Verity Pharmaceuticals Inc., Lawley Pharmaceuticals Pty Ltd.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/androgen-deprivation-therapy-global-market-report

How Is Androgen Deprivation Therapy Market Adoption Varying Across Different Regions And Sectors?

North America was the largest region in the androgen deprivation therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the androgen deprivation therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=25692&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model